Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
Icelander chemical industry news
4 February 2026
Kemira Enters Finland's Top 5 in Nordic Diversity Index
Kemira improved its diversity ranking, focusing on gender, age, nationality, and education. The 2026 report highlights AI's role in digital leadership.
7 January 2026
Grupa Azoty Secures Multi-Year Fertiliser Deal in Scandinavia
The contract enhances export strategy, ensuring stable fertiliser supply to Scandinavia, meeting high standards and boosting sales in a key market.
12 December 2025
Merck's WINREVAIR™ Gains EU CHMP Support for Broader PAH Use
EU CHMP backs expanded WINREVAIR™ use for PAH, covering WHO FC II-IV. Decision by European Commission expected Q1 2026.
19 November 2025
Merck's KEYTRUDA® Subcutaneous Form Approved by European Commission
KEYTRUDA SC, a subcutaneous immune checkpoint inhibitor, is approved in Europe for faster administration across all adult indications.
18 November 2025
EU Imposes Safeguard Measures on Ferroalloy Imports; Impact on Elkem
The EU enacts tariff rate quotas on ferroalloy imports, effective Nov 2025 for three years, excluding silicon metal. Elkem anticipates sales shifts and potential price increases.
23 October 2025
Elkem Q3 2025: Strong Operations and Cost Improvements Boost Results
EBITDA fell 33% YoY due to low sales prices. Silicones division under review for sale. EU and US trade measures may impact future performance.
How does the Icelander chemical industry perform?
Find out with
chemXplore Analytics
Learn more
20 October 2025
Elkem Reduces Ferrosilicon Output in Norway and Iceland
Production cut due to weak European market and EU import investigation. Temporary layoffs possible. Aims to lower inventory and stabilize market.
19 September 2025
Merck's ENFLONSIA™ Recommended by EU CHMP for RSV Prevention in Infants
ENFLONSIA™ awaits EU approval for infant RSV prevention, offering a single-dose option for all weights. Backed by Phase 2b/3 and Phase 3 trials, decision expected by year-end.
19 September 2025
Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use
CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.
